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ABSTRACT
Introduction: Limited data are available on the
real-world effectiveness of newer oral disease-
modifying therapies (DMTs) inmultiple sclerosis.
The purpose of this study was to retrospectively
compare the real-world effectiveness of dimethyl
fumarate (DMF), fingolimod, teriflunomide, and
injectableDMTs in routine clinical practice based
on US claims data.
Methods: Patients newly-initiating DMF, inter-
feron beta (IFNb), glatiramer acetate (GA), teri-
flunomide, or fingolimod in 2013 were
identified in the Truven MarketScan Commer-
cial Claims Databases (N = 6372). Relapse epi-
sodes were identified based on a published
claim-based algorithm and used to determine
the annualized relapse rate (ARR) for the year
before and after initiating therapy. Poisson and
negative binomial regression was used to
determine the adjusted incidence rate ratio
(IRR) for each therapy relative to DMF.
Results: Significant ARR reductions in the year
after initiating therapy were reported for DMF
and fingolimod (P\0.0001). Compared with
DMF, the adjusted IRR (95% CI) for relapse in
the year after initiating therapy was 1.27
(1.10–1.46) for IFNb, 1.34 (1.17–1.53) for GA,
1.23 (1.05–1.45) for teriflunomide, and 1.03
(0.88–1.21) for fingolimod. Results were con-
sistent across subgroup and sensitivity analyses.
Conclusion: These real-world data suggest DMF
and fingolimod have similar effectiveness and
demonstrate superior effectiveness to IFNb, GA,
and teriflunomide.
Funding: Biogen, Cambridge, MA, USA.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic, progressive
immune-mediated disease of the central ner-
vous system in which inflammation, demyeli-
nation, and axonal degeneration lead to loss of
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neurologic function [1–3]. MS affects approxi-
mately 2.3 million individuals worldwide and
more than 570,000 individuals in the USA [4, 5],
and it has a substantial impact on patients’ daily
living and quality of life [6]. Approximately
85% of people with MS have relapsing–remit-
ting MS (RRMS), characterized by progressive
neurologic relapses interspersed with periods of
clinical remission [7].
The introduction of oral disease-modifying
therapies (DMTs), dimethyl fumarate (DMF),
fingolimod, and teriflunomide, is revolutioniz-
ing the management of MS, enabling patients
with RRMS to achieve significant reductions in
the risk of relapses and disease-related disability
with daily oral therapy instead of frequent
subcutaneous or intramuscular injections
[8–12]. Oral therapies offer the advantage of
convenience compared with injected medica-
tions and have the potential to improve com-
pliance. Given the range of therapies available
for the management of RRMS, data on the rel-
ative efficacy and safety of new therapies com-
pared with each other and with more
well-established DMTs [interferon beta (IFNb)
and glatiramer acetate (GA)] are important to
support physician and patient decisions around
treatment choice. Currently, there are no
head-to-head clinical trials of the available oral
therapies and only limited direct comparative
data regarding the safety and efficacy of newer
oral therapies versus the injected DMTs. Fin-
golimod provides better efficacy than weekly
intramuscular IFNb [9]; teriflunomide has
demonstrated comparable efficacy versus sub-
cutaneous IFNb administered three times each
week [10]; DMF has demonstrated a signifi-
cantly greater treatment effect on annualized
relapse rates (ARRs) compared with once-daily
subcutaneous GA in a post hoc analysis of clini-
cal trial data [11].
A number of indirect analyses have been
performed concerning the three oral DMTs
based on data from their respective clinical trial
programs in patients with MS [13, 14]. A
mixed-treatment comparison study reported no
significant difference in ARR for DMF and fin-
golimod and superior efficacy for DMF com-
pared with IFNb, GA, and teriflunomide [13]. A
further study using a network meta-analysis
approach reported that all three oral DMTs and
GA significantly reduced the risk of experienc-
ing at least one relapse over 1 year compared
with placebo (P\0.05); however, the risk
reduction achieved with the different IFNb
therapies did not reach statistical significance
[14]. Taken together, these results suggest that
the oral therapies provide at least comparable
efficacy to IFNb and GA and that DMF and fin-
golimod may provide superior efficacy com-
pared with teriflunomide.
Although data from clinical trials provide
important evidence of the efficacy and safety of
new therapies, real-world data are increasingly
utilized to support decision-making, based on
the value of a therapy in routine clinical prac-
tice. Such assessments typically better reflect
the patient population in which the interven-
tion is being used, which is often much less
homogeneous than the patient population
involved in a clinical trial. Similarly, factors
such as patient compliance, concomitant ther-
apy use, and stage of disease at treatment initi-
ation, which may significantly influence
outcomes, may differ in routine clinical practice
compared with a controlled clinical trial setting.
For example, a review concluded that fin-
golimod is generally initiated in routine clinical
practice in patients with MS at a later stage of
disease compared with those enrolled in the
pivotal clinical trials [15].
Various real-world studies have investigated
the comparative effectiveness of the established
injectable DMTs (IFNb and GA) and fingolimod
[16–18]. However, to date, no studies have
reported on the effectiveness of DMF or teri-
flunomide in a real-world setting. The objective
of this study was to compare the effectiveness of
available oral and injectable DMTs in a real--
world setting based on US claims data.
METHODS
Data Source
This retrospective claims analysis was based on
data from the Truven MarketScan Commercial
Claims Databases. Claims data from 2012 to
2014 were analyzed to compare the
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effectiveness of the following DMTs for the
management of MS: DMF, IFNb, GA, terifluno-
mide, and fingolimod. The Truven MarketScan
Commercial Claims Databases contain the
de-identified administrative claims and eligibil-
ity records of over 120 million commercially
insured individuals from all US regions and
include three main components: (1) claims for
medical services provided in both the inpatient
and outpatient settings with the associated
diagnosis, service dates, place of service, proce-
dures performed, and patient- and plan-paid
amounts; (2) pharmacy claims with the associ-
ated dispense date, National Drug Code, dose,
days of supply, and patient- and plan-paid
amounts; (3) patient demographic information
including year of birth, sex, and region of resi-
dence. Information on the diagnostic criteria
used for MS diagnosis, severity and duration of
MS, rate of progression, results of laboratory or
imaging tests, or measurements of neurologic or
MS-related disability, such as the expanded
disability status scale (EDSS), is not routinely
captured in claims data.
All patient information was anonymized,
and patient confidentiality was maintained
through compliance with Health Insurance
Portability and Accountability Act (HIPAA)
regulations. The analysis presented is based on
previously collected data and does not involve
any new studies of human or animal subjects
performed by any of the authors.
Patient Identification
Adult patients with MS were identified as indi-
viduals having at least one hospitalization with
an associated diagnosis suggesting MS [Inter-
national Classification of Diseases, Ninth Revi-
sion, Clinical Modification (ICD-9-CM):
diagnosis code 340] or two outpatient visits
with the same ICD-9-CM diagnosis code dated
at least 30 days apart. Patients who initiated one
of the DMTs of interest (DMF, IFNb, GA, teri-
flunomide, or fingolimod) during the 2013 cal-
endar year were identified; initiation was
defined as having no claims for the same DMT
in the prior year. Patients switching from
another DMT were included in the analysis.
Patients initiating natalizumab or alemtuzumab
during the study period were not included in
the analysis because the focus of this study was
on oral and injectable DMTs. Eligible DMT ini-
tiators were assigned to corresponding DMT
cohorts according to their initiated DMT;
patients were not randomized to treatment
cohorts. The date of DMT initiation was defined
as the index date. Patients aged between 18 and
64 years at the index date were included in the
analysis. To ensure complete data were available
for the assessment of baseline characteristics
and study outcomes, selected patients were
required to have continuous enrollment in the
Truven MarketScan Commercial Claims Data-
bases at least 1 year before and 1 year after the
index date (Fig. 1).
Study Measures
Patient demographics included age at index
date, sex, and region of residence. Baseline
clinical characteristics were assessed based on
medical and pharmacy claims dated within
1 year before the index date. Chronic disease
burden was measured using the Charlson
Comorbidity Index (CCI), a composite score
calculated based on the presence of 22 chronic
conditions (e.g., diabetes, peptic ulcer, liver
disease, cancer), with each condition being
assigned a score of 1, 2, 3, or 6 [19]. CCI was
originally designed to predict 10-year mortality
and has been widely used to assess chronic dis-
ease burden in large retrospective studies. The
proportion of patients experiencing MS-related
symptoms within 1 year prior to the index date
was assessed. The selection of symptoms as
being MS-related was based on a published
study [20] and clinical input from the research
investigators.
The ARRs 1 year before and 1 year after the
index date were calculated as the number of
relapse episodes that a patient had during a
year. Relapse episodes were identified based on
a published claims-based algorithm [21, 22]. In
our analysis, a patient was considered to have
experienced a moderate-to-severe relapse if they
were hospitalized with a primary diagnosis
suggesting MS or had an outpatient visit with at
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least one associated diagnosis suggesting MS
together with evidence of receiving high-dose
oral steroid (C500 mg/day prednisolone or
equivalent), intravenous corticosteroid, corti-
cotropin (i.e., adrenocorticotropic hormone), or
plasma exchange within 30 days of the outpa-
tient visit. As patients may have had multiple
clinical encounters during one relapse, all
qualified hospitalizations or outpatient visits
that occurred within 30 days of each other were
considered as one relapse episode.
To support subgroup analyses, adherence to
the index DMT was assessed based on the
pharmacy claims dated within 1 year following
the index date via the medication possession
ratio (MPR). MPR is estimated as the total
number of days of supply of all fills of the index
DMT within the refill interval, divided by the
number of days in the refill interval. The MPR
was calculated among patients with at least two
prescription fills, for the interval between the
first and last fill, during the 1-year follow-up
period (referred to as the refill interval). High
MPR represents good patient adherence to
DMT. Values for MPR were capped at 1.
Statistical Analysis
Distribution of baseline characteristics and
outcomes was assessed for each DMT cohort.
Percentages were presented for categorical
measures and mean and standard deviation (SD)
for continuous measures. Wilcoxon signed rank
test was used to test whether changes in ARR
before and after DMT initiation were signifi-
cantly different from zero. Study measures were
compared between each of the DMT cohorts
and the DMF cohort, which was used as the
reference group. Student t tests (continuous
variables) and chi-squared tests (categorical
variables) were used to detect significant differ-
ences between the DMF cohort and the other
cohorts.
Poisson and negative binomial regression
models were estimated to control for differences
in patient populations between the different
DMT cohorts while comparing the ARR for
1 year after the index date between DMT
cohorts. The following potential confounders
were included in the models: age categories
(18–30, 31–40, 41–50, and 51–64 years), sex,
region of residence, number of relapses experi-
enced in 1 year before the index date (0, 1, 2,
and C3), use of any other DMT during the
1 year prior to the index date, CCI score, and
the presence of individual MS-related symp-
toms. As the largest cohort included in the
study, the DMF cohort was assigned as the ref-
erence group. The adjusted incidence rate ratios
(IRRs) for relapse relative to the DMF cohort are
presented with the associated 95% confidence
interval (CI).
Subgroup analyses were conducted to ana-
lyze ARR in patients who were adherent to
treatment (defined as those having an MPR
of C0.8, C0.7, or C0.6) and patients aged
younger than 40 years. Sensitivity analyses
comprised logistic regression (to assess binary
outcomes) and using 7 days as the cut-off for
consecutive clinical encounters, which were
defined as a single relapse (compared with
30 days in the primary analysis).
Fig. 1 Patient selection ﬂow chart. DMT disease-modify-
ing therapy, ICD-9-CM International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁcation
Neurol Ther
RESULTS
A total of 6372 patients with MS meeting the
inclusion criteria were identified in the Truven
MarketScan Commercial Claims Databases
(2012–2014). Of this cohort, 52.6% of patients
initiated DMF, 13.9% initiated IFNb, 16.6%
initiated GA, 7.8% initiated teriflunomide, and
9.1% initiated fingolimod. Mean (SD) ages for
the cohorts ranged from 43.5 (10.4) years for GA
to 49.6 (8.9) years for teriflunomide (Table 1).
Between 76% and 80% of patients were female,
and the CCI scores ranged from 0.42 (0.91) for
fingolimod to 0.76 (1.33) for GA. Approxi-
mately 85% of patients in the GA and IFNb
cohorts had not received DMT in the year prior
to the index date compared with only approxi-
mately one-third of patients in the other three
cohorts. Differences in the frequency of the
MS-related symptoms identified were seen
across cohorts (Table 1).
Unadjusted ARR for the year prior to the
index date ranged from 0.31 for GA to 0.44 for
fingolimod and ranged from 0.30 for DMF to
0.35 for teriflunomide for the year after the
index date (Fig. 2). Significant reductions in
unadjusted ARR were observed in the DMF
[0.129 (30.4%) reduction, P\0.0001] and fin-
golimod [0.135 (30.5%) reduction, P\0.0001]
cohorts in the year after initiating therapy. The
greatest increases in the proportion of patients
experiencing no relapses in the year after DMT
initiation were observed in the DMF and fin-
golimod cohorts (?8.1% and ?11.6%, respec-
tively) compared with ?5.9%, ?2.9%, and
?6.2% in the IFNb, glatiramer acetate, and ter-
iflunomide cohorts, respectively. Reductions in
the proportion of patients experiencing two or
more relapses over a 1-year period were
observed in the DMF and fingolimod cohorts
[–3.8% and –1.2%, respectively, compared with
increases in the IFNb, glatiramer acetate, and
teriflunomide cohorts (?2.4%, ?4.1%, and
?1.2%, respectively)]. Data on the proportion of
patients experiencing relapses in the year before
and the year after DMT initiation are reported
in Table S1 in the supplementary material.
After Poisson regression to adjust for differ-
ences in baseline patient demographics, clinical
characteristics, and prior DMT exposure, the
adjusted IRR for relapse in the first year after
initiating therapy was compared for each ther-
apy relative to the DMF cohort. The adjusted
IRR (95% CI) was 1.03 (0.88–1.21) for fin-
golimod indicating no significant difference in
effectiveness between fingolimod and DMF.
After adjusting for confounders, the adjusted
IRRs compared with DMF were 1.27 (1.10–1.46)
for IFNb, 1.34 (1.17–1.53) for GA, and 1.23
(1.05–1.45) for teriflunomide, indicating a sta-
tistically significant effectiveness advantage for
DMF over these DMTs (Fig. 3). The number of
relapses in the year prior to DMT initiation
(P\0.0001) and the presence of fatigue or
malaise (P = 0.0011) are also significant predic-
tors for ARR after DMT initiation. Full regres-
sion analysis results are reported in Table S2 in
the supplementary material.
Adjusted IRRs for relapse in the first year after
initiating therapy were similar after negative
binomial regression. Adjusted IRRs (95% CI)
were 1.02 (0.85–1.23) for fingolimod, 1.28
(1.08–1.51) for IFNb, 1.32 (1.13–1.55) for GA,
and 1.21 (1.00–1.47) for teriflunomide. The
number of relapses in the year prior to DMT
initiation (P\0.0001) and the presence of fati-
gue or malaise (P = 0.0037) were both signifi-
cant predictors for ARR after DMT initiation.
Full regression analysis results are reported in
Table S3 in the supplementary material.
Results for subgroup analyses were consistent
with those for the overall population. The
Poisson regression adjusted IRRs for patients
who were adherent to DMT treatment (defined
as having an MPR of C0.8) demonstrated that
DMF provided a significantly lower ARR in the
post-index period than IFNb, GA, and teri-
flunomide (P\0.05 in all pair-wise compar-
isons; Fig. 4). Further subgroup analyses for
adherent patients (defined as an MPR of C0.6 or
C0.7) confirmed the significantly lower ARR in
the DMF cohort compared with the IFNb, GA,
and teriflunomide cohorts (Table S4 in the
supplementary material). Analysis of the sub-
group of patients aged younger than 40 years
demonstrated that the ARR in the post-index
period was significantly lower in the DMF
cohort than in the IFNb and GA cohorts
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Age at index date, mean (SD)
years
46.7 (9.7) 43.6 (10.8)b 43.5 (10.4)b 49.6 (8.9)b 43.8 (10.1)b \0.0001
Female, % 76.6 78.6 79.0 80.0 76.2 0.2147
Region, % b b b \0.0001
Northeast 24.2 21.9 25.8 20.4 22.5
Midwest 21.6 26.1 21.6 24.4 29.0
South 32.8 36.4 31.9 38.0 31.3
West 19.4 14.6 19.2 15.6 15.7
Unknown 2.0 0.9 1.5 1.6 1.6
Charlson Comorbidity Index
score, mean (SD)
0.52 (1.06) 0.71 (1.26)b 0.76 (1.33)b 0.65 (1.15)b 0.42 (0.91)b \0.0001
Relapses in the year before
index DMT initiation, %
b b b b
0 71.0 69.6 74.2 69.8 66.5
1 19.4 25.7 22.8 24.2 25.9
C2 9.5 4.8 3.0 6.0 7.6
MS-related symptoms, %
Other causes of myelitis 0.7 3.2b 3.7b 0.4 0.9 \0.0001
Demyelinating disease of
CNS, unspeciﬁed
7.7 17.9b 23.0b 6.2 8.1 \0.0001
Disorders of optic nerve and
visual pathways
8.4 11.5b 12.6b 6.6 11.4b \0.0001
Neurogenic bladder NOS 6.9 2.8b 3.2b 7.8 4.8 \0.0001
Other disorders of soft tissues:
neuralgia, neuritis, and
radiculitis, unspeciﬁed
2.7 3.1 4.2b 2.6 1.2b 0.0122
General symptoms: dizziness
and giddiness
7.4 13.9b 15.3b 6.8 6.0 \0.0001
General symptoms:
fatigue/malaise
26.2 26.4 29.2b 26.4 25.9 0.3767
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(P\0.05; Table S4 in the supplementary mate-
rial). Results from sensitivity analyses using
logistic regression and alternative criteria for
relapse were all consistent with the findings for
the primary analysis (data not shown).
DISCUSSION
This study, the first to report real-world com-
parative effectiveness data across all available
oral and injectable DMTs, indicates that DMF
and fingolimod have similar effectiveness for
relapse prevention in patients with MS and
demonstrate superior effectiveness to IFNb, GA,
and teriflunomide in routine clinical practice.
This finding was consistent across all subgroup
and sensitivity analyses indicating that, irre-
spective of the patient subgroup assessed, DMF
and fingolimod provide substantial and signifi-
cant reductions in ARR that are superior to
those provided by IFNb, GA, and teriflunomide.
The findings in the present study suggest an
effect of the pre-treatment relapse rate on the
on-treatment relapse rate. ARR in the pre-index
period was highest in the DMF and fingolimod
cohorts, with the largest ARR reductions
observed in the same cohorts. The findings also
suggest an effect of prior therapy on post-DMT
initiation relapse rates; approximately 85% of
patients initiating IFNb or GA had not received


















No DMT in the year prior to
the index date, %
31.3 86.5b 84.3b 34.0 35.8b \0.0001
CNS central nervous system, DMT disease-modifying therapy, MS multiple sclerosis, NOS not otherwise speciﬁed, SD
standard deviation
a P\0.05 indicates that one cohort is signiﬁcantly different from the comparator cohorts, but does not specify which
cohort is different
b Signiﬁcantly different from the dimethyl fumarate cohort (P\0.05)
Fig. 2 Unadjusted annualized relapse rates for 1 year before and 1 year after DMT initiation. DMT disease-modifying
therapy
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31–36% of patients receiving DMF, fingolimod,
or teriflunomide. Interpretation of these results
should therefore be conducted in the context of
the differences between cohorts as determinants
of pre-index ARR, such as the level of disability,
MS phenotype, and time since first MS diagno-
sis. As claims databases do not include this
information, the current analysis is unable to
control for these factors. However, these data
derived from routine clinical practice are con-
sistent with those from a mixed treatment
comparison of the comparative efficacy of DMF,
IFNb, GA, teriflunomide, and fingolimod based
on clinical trial data [13]. Our results now
extend these findings to the real-world setting
and confirm that, in routine clinical practice,
DMF is likely to provide superior outcomes for
patients compared with teriflunomide, GA, and
Fig. 3 Adjusted IRR (95% CI) of ARR for 1 year after
initiation of DMT for the interferon beta, glatiramer
acetate, teriﬂunomide, and ﬁngolimod cohorts relative to
the DMF cohort. An IRR\1.0 means that the ARR of the
comparator DMT cohort is lower than the DMF cohort,
whereas an IRR [1.0 means that the ARR of the
comparator DMT cohort is higher than the DMF cohort.
For example, an IRR for interferon beta versus DMF of
1.27 means that the ARR in the interferon beta cohort is
27% higher than that of the DMF cohort after adjusting
for baseline differences. ARR annualized relapse rate, CI
conﬁdence interval, DMF dimethyl fumarate, DMT
disease-modifying therapy, IRR incidence rate ratio
Fig. 4 Adjusted IRR (95% CI) of relapse in the ﬁrst year
after initiation of interferon beta, glatiramer acetate,
teriﬂunomide, and ﬁngolimod relative to DMF for patients
adherent to therapy (deﬁned as an MPR of C0.8). An
IRR\1.0 means that the ARR of the comparator DMT
cohort is lower than that of the DMF cohort, whereas an
IRR[1.0 means that the ARR of the comparator DMT
cohort is higher than that of the DMF cohort. For
example, an IRR for interferon beta versus DMF of 1.40
means that the ARR in the interferon beta cohort is 40%
higher than that of the DMF cohort after adjusting for
baseline differences. ARR annualized relapse rate, CI
conﬁdence interval, DMF dimethyl fumarate, DMT
disease-modifying therapy, IRR incidence rate ratio, MPR
medication possession rate
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IFNb, as well as the benefits of oral therapy, in
terms of patient convenience, compared with
the latter two parenterally administered DMTs.
The use of long-term, self-administered injec-
tions is burdensome to some patients, especially
those with a needle phobia, and is associated
with injection-related adverse events [23].
Inconvenience, needle phobia, and injec-
tion-site reactions, among others, are factors
recognized to negatively affect adherence to
therapy [23]. By contrast, the use of oral thera-
pies overcomes patient concerns relating to
needle phobia and injection-site reactions and
offers a convenient method of administration
[23].
The similar effectiveness data for DMF and
fingolimod in our analysis are consistent with
prior analyses based on the clinical trial data,
indicating that both DMTs provide an appro-
priate choice of therapy for patients with RRMS.
Moreover, the findings in the present study are
consistent with an analysis of 775 propen-
sity-matched patients with MS receiving either
DMF (n = 458) or fingolimod (n = 317) in rou-
tine clinical practice in the USA [24]. In this
analysis, there was no significant difference in
ARR, overall brain magnetic resonance imaging
activity, and discontinuations at 1 year of ther-
apy for patients receiving DMF or fingolimod
[24].
Results reported in the present study were
robust, irrespective of the subgroup or sensitiv-
ity analysis performed, and consistent with the
large number of patients included in the
analysis. Neither age (\40 years) nor adherence
to therapy (MPR of C0.8, C0.7, or C0.6) sub-
stantially impacted on the conclusions from the
primary analysis. The minimal influence of
DMT adherence on the relapse rates is impor-
tant given the potential role of adherence in
DMT effectiveness. Our findings indicate that
differences in DMT effectiveness remain robust
even with moderate decreases in DMT adher-
ence. Sensitivity analyses also had no relevant
impact on the findings from the primary anal-
ysis, irrespective of changes to the method of
analysis used (negative binomial regression or
logistics regression) and to the time frame con-
sidered as a single relapse event. Together, the
subgroup and sensitivity analyses confirm our
findings that DMF provides substantial and
significant reductions in ARR that are compa-
rable with those provided by fingolimod and
superior to those provided by IFNb, GA, and
teriflunomide.
As clinical evidence of MS relapse is not
included in claims data, relapses were identified
based on a validated algorithm derived from the
ICD-9-CM diagnosis code and details of medi-
cations dispensed. This algorithm has been used
in previous studies to determine relapse rates in
patients with RRMS based on claims data and
allows the identification of moderate-to-severe
relapses that result in a clinical encounter.
However, patients with a mild relapse may not
seek an appointment with a physician; thus,
mild relapses may be difficult to identify.
Validation of the algorithm by Chastek and
colleagues was achieved by a comparison with
medical charts and clinician review, resulting in
the classification of 67.3% of patients with
relapses (positive predictive value) and 70.0% of
patients without relapses (negative predictive
value) in a sample of 300 patients [22].
Although this approach may underestimate the
overall relapse incidence, this effect is antici-
pated to be uniform across all comparisons. We
also assessed algorithm robustness and sensi-
tivity by varying input parameters (including
using the originally published algorithm), con-
sidering outpatient visits involving plasma
exchange and high-dose oral steroid use as
identifying a relapse event and considering
clinical encounters occurring within 7 days (as
opposed to 30 days) of each other as a single
event. ARRs derived by all variations of the
algorithm were in good agreement, differing by
less than 0.1 (data not shown). Furthermore,
the ARRs reported here are in the same range as
those reported from clinical trials and are con-
sistent with the ARRs reported in studies of
real-world data [17, 25]. Our study, therefore,
provides further confirmation of the validity of
this approach for determining ARR from claims
data.
The present study is subject to a number of
the limitations associated with retrospective
studies utilizing administrative claims data. First,
data are collected for the purposes of billing and
monitoring the quality of care, not for assessing
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treatment effectiveness, and are subject to cod-
ing errors, although these are anticipated to
occur at random. Second, thedata donot contain
information on the diagnostic criteria used,
severity and duration of MS, rate of progression,
or results of laboratory or imaging tests; differ-
ences in neurologic or MS-related disability were
not measured or accounted for as this informa-
tion is not captured in claims data. These data
would allow the analysis to control for differ-
ences in cohort clinical characteristics. Future
studies are needed to develop and validate an
algorithm to control for these confounders.
Finally, MS relapses were identified from
administrative claims and do not necessarily
correspond to events as identified in clinical tri-
als (e.g., a relapse can be defined as new or
recurrent neurologic symptoms lasting for C24 h
and accompanied by new objective neurologic
findings) [26]. However, the influence of poten-
tial misclassification is not expected to bias
specific DMTs.
In this study, patients were not randomized
to treatment, and Poisson and negative bino-
mial regression was applied to account for
differences in some of the clinical and demo-
graphic variables observed in the data set.
Matching patients, through propensity score
matching, provides an alternative approach to
controlling for these variables, but would not
have eliminated any potential confounding for
the matched variables [27]. The use of regres-
sion analysis in this study maintains statistical
precision by allowing the use of all patient
information rather than discarding information
for unmatched patients [28]. Importantly, as
discussed, the results of this study were com-
parable with those reported for DMF and fin-
golimod in propensity-matched patients with
MS [24]. However, further studies are needed to
confirm whether the clinical and demographic
variables not captured in claims data influence
relapse rates in patients with MS receiving an
oral or injectable DMT.
CONCLUSION
This study provides the first real-world evi-
dence comparing the effectiveness of oral and
injectable DMTs for the management of MS
in routine clinical practice. Our results indi-
cate that there are significant differences in
the effectiveness of the different DMTs in
patients with MS. These data should assist in
treatment decisions regarding the choice of
DMT and enable clinicians to consider both
real-world effectiveness and route of admin-
istration in consultations with their patients.
Additional data are warranted to provide evi-
dence for the long-term effectiveness of the
newer oral therapies, including the impact of
these therapies on disability progression. Such
data should assist clinicians in determining
the role of the growing number of treatment
options in the management of RRMS to
achieve the maximum therapeutic benefit for
patients.
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